MARLBOROUGH, Mass. / Jul 02, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in the... Read More

Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions MARLBOROUGH, Mass. / May 22, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating the significant... Read More

MARLBOROUGH, Mass. / May 13, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences: The 2025 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20 at 9:30 a.m. Eastern Time (ET) in New York. William Blair’s 45 th Annual Growth Stock Conference in Chicago on Wednesday, June 4 at 4 p.m. Central Time The... Read More

Revenue of $1,005.3 Million Slightly Exceeds Guidance Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS MARLBOROUGH, Mass. / May 01, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 29, 2025 . “We... Read More

MGH-led study retrospectively analyzed 5,000 radiologist-reviewed screening exams using the company’s Genius AI ® Detection Solution MARLBOROUGH, Mass. / Apr 24, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) will have a strong presence at the Society of Breast Imaging (SBI) Annual Symposium in Colorado Springs, Colorado this week, including the presentation of pivotal new research conducted by a top-tier healthcare... Read More

Report highlights efforts to enhance access and equity in women's health and invest in the future with science-based environmental targets, employee development and community engagement MARLBOROUGH, Mass. / Apr 22, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a company that develops industry-leading technologies that detect, diagnose and treat life-changing health conditions that affect women, today released its... Read More

MARLBOROUGH, Mass. / Apr 04, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that Wayde McMillan has been elected to the Company’s Board of Directors, effective April 4, 2025. Mr. McMillan was also appointed to the Audit and Finance Committee effective April 4, 2025. Mr. McMillan has served as the Chief Financial Officer of Solventum Corporation, a carve-out health care company of 3M Company, since 2024... Read More

MARLBOROUGH, Mass. / Apr 03, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2025 on Thursday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the... Read More

MARLBOROUGH, Mass. / Feb 25, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Raymond James & Associates' 46th Annual Institutional Investors Conference on Tuesday, March 4 at 11 a.m. Eastern Time (ET). The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com . The webcast will... Read More

MARLBOROUGH, Mass. / Feb 18, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, which was first granted Emergency Use Authorization (EUA) status in May 2020. “Our COVID test was instrumental in addressing critical testing needs during the pandemic and offered healthcare providers and... Read More

Company Reports GAAP Diluted EPS of $0.87; Non-GAAP Diluted EPS of $1.03 at High End of Guidance Revenue of $1,021.8 Million Increases 0.9%; Constant Currency Growth of 1.0% In-Line with Guidance Company Lowers Full-Year Guidance for GAAP EPS, Maintains Guidance for Non-GAAP EPS MARLBOROUGH, Mass. / Feb 05, 2025 / Business Wire / Hologic, Inc . (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal... Read More

DAVOS, Switzerland / Jan 21, 2025 / Business Wire / Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index , one of the largest collections of data on women’s health and well-being. Hologic, Inc. (Nasdaq: HOLX), a leading women’s health innovator, partners with Gallup to create the Index. Now in its fourth year, the Index raises new concerns about declining trends in women’s... Read More

Revenue of $1,021.8 Million Grows 0.9% Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges MARLBOROUGH, Mass. / Jan 12, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024. The Company expects to report total revenues of approximately... Read More

MARLBOROUGH, Mass. / Dec 18, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests used to identify specific diseases... Read More

MARLBOROUGH, Mass. / Dec 10, 2024 / Business Wire / Hologic, Inc. , (Nasdaq: HOLX) a global leader in women’s health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening: “Today’s recommendations are an important... Read More

MARLBOROUGH, Mass. / Dec 09, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that Martin Madaus has been elected to the Company’s Board of Directors, effective December 6, 2024. Dr. Madaus was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective... Read More

Study Assesses Prognostic Value of BCI Testing and Its Potential in Supporting De-escalation of Primary Adjuvant Endocrine Therapy MARLBOROUGH, Mass. / Dec 09, 2024 / Business Wire / Four new studies regarding the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these studies, initial data will be premiered investigating the potential role of the BCI test to... Read More

Leader in Women’s Health Unveils Data Underscoring Its Commitment to Reducing Bias in Breast Cancer Detection MARLBOROUGH, Mass. / Dec 02, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) yesterday presented new research demonstrating the performance of its Genius AI ® Detection 2.0 software across diverse patient... Read More

Leader in Women’s Health Will Unveil Groundbreaking Innovations With a Focus on Imaging Solutions and Artificial Intelligence MARLBOROUGH, Mass. / Nov 25, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) will reveal new technologies reimagining the future of breast health at the 110 th Scientific Assembly and Annual Meeting... Read More

MARLBOROUGH, Mass. / Nov 14, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences: 2024 Stephens Annual Investment Conference in Nashville, TN on Thursday, November 21 st , at 10 a.m. Central Time (CT). 7 th Annual Evercore ISI HealthCONx Conference in Coral Gables, FL on Tuesday, December 3 rd , at 2:10 p.m. Eastern Time (ET). Citi’s... Read More

Revenue of $987.9 Million, GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01 Total Company Revenue Growth of 4.5%, or 4.2% in Constant Currency and 5.0% Organically ex. COVID-19 in Constant Currency Company Expects Strong Execution of its Broad-Based Growth Strategy in Fiscal 2025 MARLBOROUGH, Mass. / Nov 04, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the... Read More

MARLBOROUGH, Mass. / Oct 14, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global champion of women’s health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health for approximately $350 million, subject to working capital and other customary closing... Read More

MARLBOROUGH, Mass. / Oct 04, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the... Read More

Company Kicks Off October by Ringing Nasdaq Opening Bell, Releasing Educational Resources for Women MARLBOROUGH, Mass. / Sep 30, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, will kick off Breast Cancer Awareness Month by ringing the Nasdaq opening bell for the 18 th year. As part of... Read More

MARLBOROUGH, Mass. / Aug 29, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Morgan Stanley 22 nd Annual Global Healthcare Conference in New York on Thursday, September 5 th , at 12:20 p.m. Eastern Time. The fire-side chat presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com.... Read More

Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Year Period MARLBOROUGH, Mass. / Jul 29, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third... Read More

MARLBOROUGH, Mass. / Jul 25, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Endomagnetics Ltd (Endomag), a privately held UK-based developer of breast cancer surgery technologies, for approximately $310 million. “We are thrilled to... Read More

New Survey Reveals Women Struggle to Prioritize Their Health MARLBOROUGH, Mass. / Jul 09, 2024 / Business Wire / Millions of women in the United States have missed screenings for serious, often life-threatening conditions, according to a new survey released today by women’s health innovator Hologic, Inc. (Nasdaq: HOLX). The... Read More

MARLBOROUGH, Mass. / Jul 02, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2024 on Monday, July 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the... Read More

MARLBOROUGH, Mass. / May 21, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences: 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29 th at 10 a.m. Central Time (CT). William Blair 44 th Annual Growth Stock Conference in Chicago, Illinois on Tuesday, June 4 th at 8:40 a.m. CT. Each... Read More

Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance Total Company Organic Revenue Growth Excluding COVID-19 of 4.9% in Constant Currency; Against a 21.9% Prior Year Period Comparable Company Raises Full-Year Revenue Midpoint in Constant Currency and Raises EPS Guidance on Strong Margins MARLBOROUGH, Mass. / May 02, 2024 / Business Wire... Read More

MARLBOROUGH, Mass. / Apr 29, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments. “Endomag’s suite of solutions complements our... Read More

MARLBOROUGH, Mass. / Apr 02, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 256-1007 (in the... Read More

Results From a Large-Scale Prospective Study Investigating Long-Term Anti-Estrogen Therapy Recommendations Published in JNCCN — Journal of the National Comprehensive Cancer Network MARLBOROUGH, Mass. / Mar 05, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced newly published study results revealing that use of the Breast Cancer Index ® (BCI) test led to physicians... Read More

Global Leader in Women’s Health to Present Research and Educational Opportunities Focused on Improving Workflow and Efficiency MARLBOROUGH, Mass. / Feb 27, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) continues to deliver on its commitment to advancing women’s health by unveiling new research in artificial intelligence (AI) and offering innovative educational opportunities at the annual European Congress of Radiology... Read More

MARLBOROUGH, Mass. / Feb 26, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences: Raymond James' 45th Annual Institutional Investors Conference on Monday, March 4 at 8:40 a.m. Eastern Time (ET). Needham Virtual Healthcare Conference on Tuesday, April 9 at 11:45 a.m. ET. Each presentation will be webcast live and may be accessed... Read More

Through a Combination of Advanced Imaging and Novel Artificial Intelligence, Latest Diagnostic System for Cervical Cancer Screening Can Help More Accurately Detect Disease, Improve Workflow and Enhance Patient Care MARLBOROUGH, Mass. / Feb 01, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that its new... Read More

Revenue of $1,013.1 Million, GAAP Diluted EPS of $1.03, and Non-GAAP Diluted EPS of $0.98; All Exceed Guidance Total Company Organic Revenue Growth Excluding COVID-19 of 5.2% in Constant Currency Against Four Fewer Selling Days Compared to the Prior Year Period Company Increases Full-Year Revenue and EPS Guidance MARLBOROUGH, Mass. / Feb 01, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s... Read More

Third annual Hologic Global Women’s Health Index shows billions of women untested for life-threatening conditions, emotional health worsening and nearly 1 billion women living with physical pain. Taiwan tops rankings of women’s health by country/territory; U.S. falls to number 30. DAVOS, Switzerland / Jan 16, 2024 / Business Wire / The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according... Read More

Leader in Women’s Health Encourages Women to Stop Suffering in Silence and Talk to Their Doctor About Disruptive Period Symptoms MARLBOROUGH, Mass. / Jan 11, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced its new uterine health education and awareness campaign Better is Possible ™. Launching in New York, Los Angeles, Atlanta and Detroit, the campaign seeks to increase... Read More

Revenue of $1,013.1 Million Exceeds Guidance 5.2% Organic Constant Currency Revenue Growth ex. COVID-19, also Exceeding Guidance MARLBOROUGH, Mass. / Jan 07, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 30, 2023. The Company expects to report total revenues of approximately $1,013.1 million, a decrease of (5.7%) compared to the... Read More

MARLBOROUGH, Mass. / Jan 04, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the... Read More

MARLBOROUGH, Mass. / Jan 02, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. Pacific Time. The presentation and Q&A session will be webcast live and may be accessed through a link on the Investors section of Hologic’s website at http://investors.hologic.com . The webcast will be... Read More

Platform Will Focus on Technologies to Detect Lung Cancer, the Leading Cause of Cancer Deaths NEW YORK & MARLBOROUGH, Mass. / Nov 30, 2023 / Business Wire / KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator. The new platform, named Maverix Medical, will be managed by... Read More

Leader in Women’s Health Will Highlight New Imaging Solutions That Aid in Cancer Detection and Radiologist Workflow MARLBOROUGH, Mass. / Nov 24, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) will showcase several recent developments in next-generation AI solutions at the 109 th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 26 to 30. On the show floor and during... Read More

MARLBOROUGH, Mass. / Nov 21, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 6 th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 2:10 p.m. Eastern Time. The fire-side chat presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com . The webcast will be... Read More

Revenue of $945.3 Million, GAAP Diluted EPS of $0.37, and Non-GAAP Diluted EPS of $0.89 Total Company Organic Revenue Growth excluding COVID-19 of 16.7% in constant currency Expect Broad Based Strong Performance in Fiscal 2024 MARLBOROUGH, Mass. / Nov 09, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 30, 2023 . “Hologic... Read More

Partnership to Include Integration of Hologic Products, Specifically Designed for Gynecologic Care, into Hands-On Skills Education for OB-GYN Residents MARLBOROUGH, Mass. / Oct 10, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced an innovative new partnership with the American Association of Gynecologic Laparoscopists (AAGL) and Inovus Medical. Hologic becomes the chief... Read More

MARLBOROUGH, Mass. / Oct 05, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2023 on Thursday, November 9, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in... Read More

Launches Global Partnership With Know Your Lemons, Will Ring Nasdaq Opening Bell for 17 th Time MARLBOROUGH, Mass. / Sep 29, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced a series of activities promoting the importance of breast cancer screenings throughout Breast... Read More

MARLBOROUGH, Mass. / Sep 22, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that Nanaz Mohtashami has been elected to the Company’s Board of Directors, effective September 20, 2023. Ms. Mohtashami was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective September 20, 2023. Ms. Mohtashami is a Managing Director at Russell Reynolds Associates, a... Read More

MARLBOROUGH, Mass. / Aug 30, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, September 6 at 9:30 a.m. Eastern Time (ET). Morgan Stanley’s 21 st Annual Global Healthcare Conference in New York, NY on Tuesday, September 12 at 9:30 a.m. ET. Each presentation will be... Read More

Revenue of $984.4 Million, GAAP Diluted EPS of ($0.16), and Non-GAAP Diluted EPS of $0.93 Total Company Organic Revenue Growth excluding COVID-19 of 18.4% in constant currency Each Business Grows Double-Digits MARLBOROUGH, Mass. / Jul 31, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended July 1, 2023 . “Hologic again delivered solid,... Read More

MARLBOROUGH, Mass. / Jul 05, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2023 on Monday, July 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (877) 400-0505 (in the... Read More

Multiplexed Respiratory Test Now Available in the U.S. With New RespDirect Collection Kit MARLBOROUGH, Mass. / May 19, 2023 / Business Wire / Hologic Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay.... Read More

MARLBOROUGH, Mass. , May 16, 2023 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced a new partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale , to educate women on the importance of prioritizing annual mammograms and other key health screenings. Ringo is a two-time national champion from the University of Georgia who was... Read More

Ringo and His Mother Will Reinforce the Importance of Annual Mammograms MARLBOROUGH, Mass. / May 08, 2023 / Business Wire / Hologic Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced a partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to... Read More

MARLBOROUGH, Mass. / May 02, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the BofA Securities 2023 Healthcare Conference in Las Vegas, NV on Tuesday, May 9 at 2:20 p.m. Pacific Time. The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com . The webcast will be available for 30... Read More

Revenue of $1,026.5 Million, GAAP Diluted EPS of $0.87, and Non-GAAP Diluted EPS of $1.06 All Exceed Guidance Total Company Organic Revenue Growth excluding COVID-19 Exceeds 20%; Each Business Delivers Strong Performance Company Raises Fiscal 2023 Revenue and EPS Guidance MARLBOROUGH, Mass. / May 01, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second... Read More

MARLBOROUGH, Mass. / Apr 03, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2023 on Monday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 600-4862 (in the... Read More

MARLBOROUGH, Mass. / Feb 28, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. Eastern Time (E.T.) Cowen’s 43 rd Annual Health Care Conference is taking place March 6 - 8, 2023, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and... Read More

MARLBOROUGH, Mass. / Feb 21, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the publishing of “Making a World of Difference,” its latest annual report detailing the company’s sustainability strategy and achievements. The report highlights how Hologic’s purpose – to enable healthier lives everywhere, every day – drives a commitment to developing medical technology innovations that generate robust... Read More

MARLBOROUGH, Mass. / Feb 17, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit unanimously affirmed a 2021 district court ruling that invalidated a Minerva patent asserted against Hologic. The appellate court ruled that Minerva’s patent is invalid because it waited more than a year to file a patent application after showing a prototype of the invention... Read More

Revenue of $1,074 Million, GAAP Diluted EPS of $0.75, and Non-GAAP Diluted EPS of $1.07 All Exceed Guidance Broad-Based Organic Revenue Growth ex. COVID-19; Diagnostics and Surgical Grow Double-Digits in Constant Currency Company Increases Full-Year Revenue and EPS Guidance MARLBOROUGH, Mass. / Feb 01, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first... Read More

Revenue of $1,074.2 Million Exceeds Guidance 15.8% Organic Constant Currency Growth in Diagnostics ex-COVID 24.5% Organic Constant Currency Growth in Molecular Diagnostics ex-COVID 14.7% Organic Constant Currency Growth in Surgical Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 31, 2022. The Company expects to report total revenues of approximately... Read More

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2023 on Wednesday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (877) 502-9276 (in the United States and Canada) or +1 (773)-305-6867... Read More

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time. The presentation and Q&A session will be webcast live and may be accessed through a link on the Investors section of Hologic’s website at http://investors.hologic.com . The webcast will be available for 30 days following the event. About... Read More

The Breast Cancer Index Test Is the First Biomarker to Predict Treatment Benefit in the SOFT Trial MARLBOROUGH, Mass.--( BUSINESS WIRE )-- Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new study data showing that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive (HR+) breast cancer benefited from the addition of ovarian... Read More